• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磁共振扩散加权成像表观扩散系数值在肝细胞癌与肝内胆管癌鉴别诊断中的比较

Comparison of Apparent Diffusion Coefficient Values on Diffusion-Weighted MRI for Differentiating Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.

作者信息

Konošenoka Katrīna Marija, Zdanovskis Nauris, Kratovska Aina, Šilovs Artūrs, Zaiceva Veronika

机构信息

Department of Radiology, Riga Stradins University, Dzirciema Street, 16, LV-1007 Riga, Latvia.

Department of Interventional Radiology, Riga East University Hospital, Hippocrates St., 2, LV-1038 Riga, Latvia.

出版信息

Diagnostics (Basel). 2025 Jul 24;15(15):1861. doi: 10.3390/diagnostics15151861.

DOI:10.3390/diagnostics15151861
PMID:40804826
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12346447/
Abstract

: Accurate noninvasive differentiation between hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) remains a clinical challenge. This study aimed to assess the dignostic performance of apparent diffusion coefficient (ADC) values from diffusion-weighted MRI in distinguishing between HCC and ICC, with histological confirmation as the gold standard. : A retrospective analysis was performed on 61 patients (41 HCC, 20 ICC) who underwent liver MRI and percutaneous biopsy between 2019 and 2024. ADC values were measured from diffusion-weighted sequences (b-values of 0, 500, and 1000 s/mm), and regions of interest were placed over solid tumor areas. Statistical analyses included -tests, one-way ANOVA, and ROC curve analysis. : Mean ADC values did not differ significantly between HCC (1.09 ± 0.19 × 10 mm/s) and ICC (1.08 ± 0.11 × 10 mm/s). ROC analysis showed poor discriminative ability (AUC = 0.520; = 0.806). In HCC, ADC values decreased with lower differentiation grades ( = 0.008, η = 0.224). No significant trend was observed in ICC ( = 0.410, η = 0.100). Immunohistochemical markers such as CK-7, Glypican 3, and TTF-1 showed significant diagnostic value between tumor subtypes. : ADC values have limited utility for distinguishing HCC from ICC but may aid in HCC grading. Immunohistochemistry remains essential for accurate diagnosis, especially in poorly differentiated tumors. Further studies with larger cohorts are recommended to improve noninvasive diagnostic protocols.

摘要

肝细胞癌(HCC)和肝内胆管癌(ICC)之间准确的无创鉴别仍然是一项临床挑战。本研究旨在评估扩散加权磁共振成像(MRI)的表观扩散系数(ADC)值在区分HCC和ICC方面的诊断性能,并以组织学确诊作为金标准。

对2019年至2024年间接受肝脏MRI检查和经皮活检的61例患者(41例HCC,20例ICC)进行回顾性分析。从扩散加权序列(b值为0、500和1000 s/mm²)测量ADC值,并将感兴趣区域置于实体瘤区域上。统计分析包括t检验、单因素方差分析和ROC曲线分析。

HCC(1.09±0.19×10⁻³mm²/s)和ICC(1.08±0.11×10⁻³mm²/s)的平均ADC值差异无统计学意义。ROC分析显示鉴别能力较差(AUC = 0.520;P = 0.806)。在HCC中,ADC值随分化程度降低而降低(P = 0.008,η² = 0.224)。在ICC中未观察到显著趋势(P = 0.410,η² = 0.100)。细胞角蛋白7(CK-7)、磷脂酰肌醇蛋白聚糖3(Glypican 3)和甲状腺转录因子1(TTF-1)等免疫组化标志物在肿瘤亚型之间显示出显著的诊断价值。

ADC值在区分HCC和ICC方面的效用有限,但可能有助于HCC分级。免疫组化对于准确诊断仍然至关重要,尤其是在低分化肿瘤中。建议进行更大样本量的进一步研究以改进无创诊断方案。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73de/12346447/a729022ac994/diagnostics-15-01861-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73de/12346447/abeffa991a6b/diagnostics-15-01861-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73de/12346447/aaa817490fa2/diagnostics-15-01861-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73de/12346447/c94e9d814b72/diagnostics-15-01861-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73de/12346447/a729022ac994/diagnostics-15-01861-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73de/12346447/abeffa991a6b/diagnostics-15-01861-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73de/12346447/aaa817490fa2/diagnostics-15-01861-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73de/12346447/c94e9d814b72/diagnostics-15-01861-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/73de/12346447/a729022ac994/diagnostics-15-01861-g004.jpg

相似文献

1
Comparison of Apparent Diffusion Coefficient Values on Diffusion-Weighted MRI for Differentiating Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.磁共振扩散加权成像表观扩散系数值在肝细胞癌与肝内胆管癌鉴别诊断中的比较
Diagnostics (Basel). 2025 Jul 24;15(15):1861. doi: 10.3390/diagnostics15151861.
2
Diagnostic Utility of Diffusion-Weighted MRI and Apparent Diffusion Coefficient Values in Differentiating Metastatic From Non-metastatic Lymph Nodes in Cervical Carcinoma.扩散加权磁共振成像及表观扩散系数值在鉴别宫颈癌转移性与非转移性淋巴结中的诊断效用
Cureus. 2025 Jun 4;17(6):e85371. doi: 10.7759/cureus.85371. eCollection 2025 Jun.
3
Amide proton transfer-weighted MRI distinguishes hepatocellular carcinoma from mass-forming intrahepatic cholangiocarcinoma.酰胺质子转移加权磁共振成像可区分肝细胞癌与肿块型肝内胆管癌。
Magn Reson Imaging. 2025 Nov;123:110491. doi: 10.1016/j.mri.2025.110491. Epub 2025 Aug 9.
4
Diffusion weighted imaging for improving the diagnostic performance of screening breast MRI: impact of apparent diffusion coefficient quantitation methods and cutoffs.扩散加权成像用于提高乳腺磁共振成像筛查的诊断性能:表观扩散系数定量方法及临界值的影响
Front Oncol. 2024 Dec 20;14:1437506. doi: 10.3389/fonc.2024.1437506. eCollection 2024.
5
Performance of Ultrasonography-Based Fractal Parameters in Distinguishing Hepatocellular Carcinoma From Intrahepatic Cholangiocarcinoma.基于超声的分形参数在鉴别肝细胞癌与肝内胆管癌中的性能
Ultrason Imaging. 2025 Jul;47(3-4):115-124. doi: 10.1177/01617346251330257. Epub 2025 Apr 15.
6
Performance of apparent diffusion coefficient values and ratios for the prediction of prostate cancer aggressiveness across different MRI acquisition settings.在不同 MRI 采集设置下,表观扩散系数值和比值对预测前列腺癌侵袭性的性能。
Diagn Interv Radiol. 2022 Jan;28(1):12-20. doi: 10.5152/dir.2022.20732.
7
CPZ: A Highly Sensitive Diagnostic Biomarker for the Differentiation Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma, Particularly in Poorly Differentiated Hepatocellular Carcinoma.CPZ:一种用于区分肝细胞癌和肝内胆管癌的高敏诊断生物标志物,尤其适用于低分化肝细胞癌。
Am J Surg Pathol. 2025 Jul 1;49(7):711-729. doi: 10.1097/PAS.0000000000002393. Epub 2025 Apr 7.
8
Comparison of diffusion-weighted and contrast-enhanced MRI for monitoring response to neoadjuvant therapy in breast cancer.扩散加权磁共振成像与对比增强磁共振成像在监测乳腺癌新辅助治疗反应中的比较
Eur Radiol. 2025 Jun 24. doi: 10.1007/s00330-025-11640-y.
9
Clinical value of conventional magnetic resonance imaging combined with diffusion-weighted imaging in predicting pelvic lymph node metastasis of cervical cancer.常规磁共振成像联合弥散加权成像在预测宫颈癌盆腔淋巴结转移中的临床价值。
Front Oncol. 2023 Dec 22;13:1267598. doi: 10.3389/fonc.2023.1267598. eCollection 2023.
10
Multi-b-value diffusion-weighted imaging-derived parameters for differentiating high-grade serous ovarian carcinoma from other epithelial ovarian cancers.用于鉴别高级别浆液性卵巢癌与其他上皮性卵巢癌的多b值扩散加权成像衍生参数。
Jpn J Radiol. 2025 Jul 1. doi: 10.1007/s11604-025-01813-6.

本文引用的文献

1
Association between radiomics of diffusion-weighted imaging and histopathology in hepatocellular carcinoma. A preliminary investigation.肝细胞癌中扩散加权成像的影像组学与组织病理学之间的关联:一项初步研究。
Magn Reson Imaging. 2025 May;118:110356. doi: 10.1016/j.mri.2025.110356. Epub 2025 Feb 11.
2
Multiparametric magnetic resonance imaging-derived radiomics for the prediction of Ki67 expression in intrahepatic cholangiocarcinoma.基于多参数磁共振成像的放射组学预测肝内胆管癌中Ki67的表达
Acta Radiol. 2025 Apr;66(4):368-378. doi: 10.1177/02841851241310394. Epub 2025 Feb 12.
3
Editorial: The 2024 Revision of the Declaration of Helsinki and its Continued Role as a Code of Ethics to Guide Medical Research.
社论:《赫尔辛基宣言》的 2024 年修订版及其作为指导医学研究的道德准则的持续作用。
Med Sci Monit. 2024 Dec 1;30:e947428. doi: 10.12659/MSM.947428.
4
Recent Advances in Pathology of Intrahepatic Cholangiocarcinoma.肝内胆管癌病理学的最新进展
Cancers (Basel). 2024 Apr 17;16(8):1537. doi: 10.3390/cancers16081537.
5
Mean ADC values and arterial phase hyperintensity discriminate small (≤ 3 cm) well-differentiated hepatocellular carcinoma from dysplastic nodule.平均 ADC 值和动脉期高信号可鉴别直径≤3cm 的分化良好的小肝癌与异型增生结节。
Abdom Radiol (NY). 2024 Apr;49(4):1132-1143. doi: 10.1007/s00261-023-04171-x. Epub 2024 Jan 30.
6
Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments.肝内胆管癌生物标志物:迈向早期检测和个体化药物治疗。
Mol Cell Probes. 2024 Feb;73:101951. doi: 10.1016/j.mcp.2024.101951. Epub 2024 Jan 20.
7
Histopathological Variants of Hepatocellular Carcinomas: an Update According to the 5th Edition of the WHO Classification of Digestive System Tumors.肝细胞癌的组织病理学变异:根据世界卫生组织消化系统肿瘤分类第5版的更新
J Liver Cancer. 2020 Mar;20(1):17-24. doi: 10.17998/jlc.20.1.17. Epub 2020 Mar 31.
8
Apparent diffusion coefficient correlates with different histopathological features in several intrahepatic tumors.表观扩散系数与多种肝内肿瘤的不同组织病理学特征相关。
Eur Radiol. 2023 Sep;33(9):5955-5964. doi: 10.1007/s00330-023-09788-6. Epub 2023 Jun 22.
9
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma.美国肝病研究学会肝细胞癌预防、诊断和治疗实践指南。
Hepatology. 2023 Dec 1;78(6):1922-1965. doi: 10.1097/HEP.0000000000000466. Epub 2023 May 22.
10
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma.欧洲肝脏研究学会-国际肝脏癌症协会《肝内胆管癌管理临床实践指南》。
J Hepatol. 2023 Jul;79(1):181-208. doi: 10.1016/j.jhep.2023.03.010. Epub 2023 Apr 20.